

Thomas Martin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/691102/publications.pdf>

Version: 2024-02-01

196
papers

11,253
citations

25014

57
h-index

40954

93
g-index

197
all docs

197
docs citations

197
times ranked

7627
citing authors

#	ARTICLE	IF	CITATIONS
1	Pyrrrolidinyl Synthetic Cathinones $\hat{\pm}$ -PHP and 4F- $\hat{\pm}$ -PVP Metabolite Profiling Using Human Hepatocyte Incubations. <i>International Journal of Molecular Sciences</i> , 2021, 22, 230.	1.8	9
2	Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized and Oral Cannabis Administration in Frequent and Occasional Cannabis Users. <i>Journal of Analytical Toxicology</i> , 2020, 44, 651-660.	1.7	12
3	Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study. <i>Translational Psychiatry</i> , 2020, 10, 71.	2.4	48
4	Correlation of creatinine and specific gravity normalized free and glucuronidated urine cannabinoid concentrations following smoked, vaporized, and oral cannabis in frequent and occasional cannabis users. <i>Drug Testing and Analysis</i> , 2019, 11, 968-975.	1.6	17
5	Metabolism of the new synthetic cannabinoid EG-018 in human hepatocytes by high-resolution mass spectrometry. <i>Forensic Toxicology</i> , 2018, 36, 304-312.	1.4	10
6	Optimization of recombinant $\hat{\pm}$ -glucuronidase hydrolysis and quantification of eight urinary cannabinoids and metabolites by liquid chromatography tandem mass spectrometry. <i>Drug Testing and Analysis</i> , 2018, 10, 518-529.	1.6	22
7	Quantification of ethyl glucuronide, ethyl sulfate, nicotine, and its metabolites in human fetal liver and placenta. <i>Forensic Toxicology</i> , 2018, 36, 102-112.	1.4	6
8	Pharmacodynamic Effects, Pharmacokinetics, and Metabolism of the Synthetic Cannabinoid AM-2201 in Male Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 367, 543-550.	1.3	17
9	Decreased Cannabinoid CB1 Receptors in Male Tobacco Smokers Examined With Positron Emission Tomography. <i>Biological Psychiatry</i> , 2018, 84, 715-721.	0.7	23
10	Synthetic cannabinoid BB-22 (QUCHIC): Human hepatocytes metabolism with liquid chromatography-high resolution mass spectrometry detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 157, 27-35.	1.4	21
11	Recent Self-Reported Cannabis Use Is Associated With the Biometrics of Delta-9-Tetrahydrocannabinol. <i>Journal of Studies on Alcohol and Drugs</i> , 2018, 79, 441-446.	0.6	21
12	Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. <i>PLoS ONE</i> , 2018, 13, e0190768.	1.1	88
13	In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201). <i>Forensic Toxicology</i> , 2017, 35, 20-32.	1.4	31
14	Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration. <i>Journal of Applied Toxicology</i> , 2017, 37, 922-932.	1.4	29
15	Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes. <i>AAPS Journal</i> , 2017, 19, 568-577.	2.2	25
16	Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting $\hat{\pm}$ -9-Tetrahydrocannabinol in Blood and Oral Fluid following Cannabis Brownie Administration. <i>Clinical Chemistry</i> , 2017, 63, 647-662.	1.5	44
17	Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration. <i>Drug and Alcohol Dependence</i> , 2017, 175, 67-76.	1.6	65
18	The acute effect of cannabis on plasma, liver and brain ammonia dynamics, a translational study. <i>European Neuropsychopharmacology</i> , 2017, 27, 679-690.	0.3	13

#	ARTICLE	IF	CITATIONS
19	On-site oral fluid δ^9 -tetrahydrocannabinol (THC) screening after controlled smoked, vaporized, and oral cannabis administration. <i>Forensic Toxicology</i> , 2017, 35, 133-145.	1.4	13
20	Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-Resolution Mass Spectrometry. <i>Clinical Chemistry</i> , 2017, 63, 1008-1021.	1.5	48
21	In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry. <i>Forensic Toxicology</i> , 2017, 35, 252-262.	1.4	7
22	Human Hepatocyte Metabolism of Novel Synthetic Cannabinoids MN-18 and Its 5-Fluoro Analog 5F-MN-18. <i>Clinical Chemistry</i> , 2017, 63, 1753-1763.	1.5	11
23	Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses. <i>Drug and Alcohol Dependence</i> , 2017, 180, 68-75.	1.6	34
24	Tobacco Exposure and Conditional Weight-for-Length Gain by 2 Years of Age. <i>Journal of Pediatric Psychology</i> , 2017, 42, 679-688.	1.1	7
25	Long-term stability of cannabinoids in oral fluid after controlled cannabis administration. <i>Drug Testing and Analysis</i> , 2017, 9, 143-147.	1.6	27
26	Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats. <i>Neuropsychopharmacology</i> , 2017, 42, 649-660.	2.8	27
27	Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration. <i>Drug Testing and Analysis</i> , 2017, 9, 905-915.	1.6	80
28	In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid. <i>Current Neuropharmacology</i> , 2017, 15, 682-691.	1.4	39
29	Free and Glucuronide Whole Blood Cannabinoids' Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake. <i>Clinical Chemistry</i> , 2016, 62, 1579-1592.	1.5	139
30	MDMA Impairs Response to Water Intake in Healthy Volunteers. <i>Advances in Pharmacological Sciences</i> , 2016, 2016, 1-11.	3.7	6
31	A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis. <i>Journal of Pain Research</i> , 2016, Volume 9, 587-598.	0.8	38
32	Metabolic characterization of AH-7921, a synthetic opioid designer drug: <i>in vitro</i> metabolic stability assessment and metabolite identification, evaluation of <i>in silico</i> prediction, and <i>in vivo</i> confirmation. <i>Drug Testing and Analysis</i> , 2016, 8, 779-791.	1.6	33
33	Cannabis effects on driving longitudinal control with and without alcohol. <i>Journal of Applied Toxicology</i> , 2016, 36, 1418-1429.	1.4	77
34	Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships. <i>Drug Testing and Analysis</i> , 2016, 8, 690-701.	1.6	38
35	Naloxone and Metabolites Quantification in Cord Blood of Prenatally Exposed Newborns and Correlations with Maternal Concentrations. <i>AJP Reports</i> , 2016, 06, e385-e390.	0.4	15
36	Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes. <i>Forensic Toxicology</i> , 2016, 34, 256-267.	1.4	21

#	ARTICLE	IF	CITATIONS
37	First metabolic profile of PV8, a novel synthetic cathinone, in human hepatocytes and urine by high-resolution mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 4845-4856.	1.9	34
38	Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [¹¹ C]CURB. <i>Biological Psychiatry</i> , 2016, 80, 691-701.	0.7	53
39	Simultaneous quantification of buprenorphine, naloxone and phase I and II metabolites in plasma and breastmilk by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2016, 1446, 70-77.	1.8	19
40	Pharmacodynamic effects and relationships to plasma and oral fluid pharmacokinetics after intravenous cocaine administration. <i>Drug and Alcohol Dependence</i> , 2016, 163, 116-125.	1.6	18
41	Drug Recognition Expert (DRE) examination characteristics of cannabis impairment. <i>Accident Analysis and Prevention</i> , 2016, 92, 219-229.	3.0	49
42	Metabolism of Carfentanil, an Ultra-Potent Opioid, in Human Liver Microsomes and Human Hepatocytes by High-Resolution Mass Spectrometry. <i>AAPS Journal</i> , 2016, 18, 1489-1499.	2.2	69
43	Cocaine and benzoylecgonine oral fluid on-site screening and confirmation. <i>Drug Testing and Analysis</i> , 2016, 8, 296-303.	1.6	13
44	Simultaneous quantification of 11 cannabinoids and metabolites in human urine by liquid chromatography tandem mass spectrometry using WAX-S tips. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 6461-6471.	1.9	49
45	Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 32, 93-117.	0.8	113
46	Synthetic cathinone pharmacokinetics, analytical methods, and toxicological findings from human performance and postmortem cases. <i>Drug Metabolism Reviews</i> , 2016, 48, 237-265.	1.5	60
47	Quantification of [1-(5-fluoropentyl)-1H-indol-3-yl](naphthalene-1-yl)methanone (AM-2201) and 13 metabolites in human and rat plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2016, 1451, 97-106.	1.8	6
48	Quantification of cannabinoids and their free and glucuronide metabolites in whole blood by disposable pipette extraction and liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2016, 1453, 34-42.	1.8	48
49	Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance. <i>Drug Testing and Analysis</i> , 2016, 8, 682-689.	1.6	33
50	Metabolic profiling of new synthetic cannabinoids AMB and 5F-AMB by human hepatocyte and liver microsome incubations and high-resolution mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2016, 30, 1067-1078.	0.7	56
51	Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. <i>Addiction Biology</i> , 2016, 21, 339-347.	1.4	83
52	School-Aged Outcomes following Prenatal Methamphetamine Exposure: 7.5-Year Follow-Up from the Infant Development, Environment, and Lifestyle Study. <i>Journal of Pediatrics</i> , 2016, 170, 34-38.e1.	0.9	32
53	Effect of Blood Collection Time on Measured ¹⁹ Tetrahydrocannabinol Concentrations: Implications for Driving Interpretation and Drug Policy. <i>Clinical Chemistry</i> , 2016, 62, 367-377.	1.5	51
54	Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administration. <i>Forensic Science International</i> , 2016, 260, 95-101.	1.3	23

#	ARTICLE	IF	CITATIONS
55	In Vitro and In Vivo Human Metabolism of Synthetic Cannabinoids FDU-PB-22 and FUB-PB-22. AAPS Journal, 2016, 18, 455-464.	2.2	50
56	Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug and Alcohol Dependence, 2016, 161, 298-306.	1.6	70
57	<i>In vitro</i> , <i>in vivo</i> and <i>in silico</i> metabolic profiling of Δ^9 -pyrrolidinopentiothiophenone, a novel thiophene stimulant. Bioanalysis, 2016, 8, 65-82.	0.6	44
58	High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human Hepatocytes. Clinical Chemistry, 2016, 62, 157-169.	1.5	65
59	In vitro stability of free and glucuronidated cannabinoids in blood and plasma collected in plastic gray-top sodium fluoride tubes following controlled smoked cannabis. Forensic Toxicology, 2016, 34, 179-185.	1.4	13
60	4-Methoxy- Δ^9 -PVP: <i>in silico</i> prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry. Forensic Toxicology, 2016, 34, 61-75.	1.4	46
61	Deterring driving under the influence of cannabis. Addiction, 2015, 110, 1697-1698.	1.7	21
62	Oral fluid with three modes of collection and plasma methamphetamine and amphetamine enantiomer concentrations after controlled intranasal Δ^9 -methamphetamine administration. Drug Testing and Analysis, 2015, 7, 877-883.	1.6	15
63	Validation of an ELISA Synthetic Cannabinoids Urine Assay. Therapeutic Drug Monitoring, 2015, 37, 661-669.	1.0	20
64	Smoked Cannabis' Psychomotor and Neurocognitive Effects in Occasional and Frequent Smokers. Journal of Analytical Toxicology, 2015, 39, 251-261.	1.7	106
65	Biochip array technology immunoassay performance and quantitative confirmation of designer piperazines for urine workplace drug testing. Analytical and Bioanalytical Chemistry, 2015, 407, 4639-4648.	1.9	20
66	Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. Clinical Chemistry, 2015, 61, 850-869.	1.5	119
67	Urinary prevalence, metabolite detection rates, temporal patterns and evaluation of suitable LC-MS/MS targets to document synthetic cannabinoid intake in US military urine specimens. Clinical Chemistry and Laboratory Medicine, 2015, 53, 423-34.	1.4	28
68	Cannabis-Impaired Driving: A Public Health and Safety Concern. Clinical Chemistry, 2015, 61, 1223-1225.	1.5	17
69	Impact of oral fluid collection device on cannabinoid stability following smoked cannabis. Drug Testing and Analysis, 2015, 7, 114-120.	1.6	22
70	Simultaneous plasma and oral fluid morphine and codeine concentrations after controlled administration of poppy seeds with known opiate content. Forensic Toxicology, 2015, 33, 235-243.	1.4	12
71	Quantification of methylone and metabolites in rat and human plasma by liquid chromatography-tandem mass spectrometry. Forensic Toxicology, 2015, 33, 202-212.	1.4	9
72	Clinical Sensitivity and Specificity of Meconium Fatty Acid Ethyl Ester, Ethyl Glucuronide, and Ethyl Sulfate for Detecting Maternal Drinking during Pregnancy. Clinical Chemistry, 2015, 61, 523-532.	1.5	75

#	ARTICLE	IF	CITATIONS
73	Antiretroviral Drugs in Meconium: Detection for Different Gestational Periods of Exposure. <i>Journal of Pediatrics</i> , 2015, 167, 305-311.e3.	0.9	6
74	Physiological reactivity during object manipulation among cigarette-exposed infants at 9 months of age. <i>Neurotoxicology and Teratology</i> , 2015, 48, 64-68.	1.2	1
75	Nicotine Metabolite Ratio (3-Hydroxycotinine/Cotinine) in Plasma and Urine by Different Analytical Methods and Laboratories: Implications for Clinical Implementation. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1239-1246.	1.1	65
76	Cannabis effects on driving lateral control with and without alcohol. <i>Drug and Alcohol Dependence</i> , 2015, 154, 25-37.	1.6	182
77	Simultaneous determination of 40 novel psychoactive stimulants in urine by liquid chromatography-high resolution mass spectrometry and library matching. <i>Journal of Chromatography A</i> , 2015, 1397, 32-42.	1.8	103
78	Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices. <i>Drug Metabolism Reviews</i> , 2015, 47, 124-174.	1.5	91
79	Cannabinoid disposition in oral fluid after controlled vaporizer administration with and without alcohol. <i>Forensic Toxicology</i> , 2015, 33, 260-278.	1.4	14
80	Identification of AB-FUBINACA metabolites in human hepatocytes and urine using high-resolution mass spectrometry. <i>Forensic Toxicology</i> , 2015, 33, 295-310.	1.4	58
81	Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA. <i>AAPS Journal</i> , 2015, 17, 660-677.	2.2	94
82	Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users. <i>Journal of Analytical Toxicology</i> , 2015, 39, 580-587.	1.7	40
83	Cocaine and metabolite concentrations in DBS and venous blood after controlled intravenous cocaine administration. <i>Bioanalysis</i> , 2015, 7, 2041-2056.	0.6	24
84	Quantification of six cannabinoids and metabolites in oral fluid by liquid chromatography-tandem mass spectrometry. <i>Drug Testing and Analysis</i> , 2015, 7, 684-694.	1.6	45
85	Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking. <i>Drug Testing and Analysis</i> , 2015, 7, 494-501.	1.6	14
86	Morphine and codeine in oral fluid after controlled poppy seed administration. <i>Drug Testing and Analysis</i> , 2015, 7, 586-591.	1.6	14
87	High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-5-fluoropentyl-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes. <i>Drug Testing and Analysis</i> , 2015, 7, 187-198.	1.6	40
88	Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens. <i>Drug Testing and Analysis</i> , 2015, 7, 483-493.	1.6	35
89	Performance characteristics of an ELISA screening assay for urinary synthetic cannabinoids. <i>Drug Testing and Analysis</i> , 2015, 7, 467-474.	1.6	29
90	Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 883-897.	1.9	116

#	ARTICLE	IF	CITATIONS
91	Mu Opioid Receptor Binding Correlates with Nicotine Dependence and Reward in Smokers. PLoS ONE, 2014, 9, e113694.	1.1	36
92	Quantification of cocaine and metabolites in exhaled breath by liquid chromatography-high-resolution mass spectrometry following controlled administration of intravenous cocaine. Analytical and Bioanalytical Chemistry, 2014, 406, 6213-6223.	1.9	25
93	In Reply. Clinical Chemistry, 2014, 60, 1236-1237.	1.5	1
94	Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment. American Journal on Addictions, 2014, 23, 234-242.	1.3	58
95	Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers. Drug Testing and Analysis, 2014, 6, 1002-1010.	1.6	30
96	Commentary. Clinical Chemistry, 2014, 60, 1484-1485.	1.5	0
97	Re: "Trends in Alcohol and Other Drugs Detected in Fatally Injured Drivers in the United States, 1999-2010". American Journal of Epidemiology, 2014, 180, 862-863.	1.6	7
98	Current knowledge on cannabinoids in oral fluid. Drug Testing and Analysis, 2014, 6, 88-111.	1.6	84
99	In vitro stability of free and glucuronidated cannabinoids in urine following controlled smoked cannabis. Analytical and Bioanalytical Chemistry, 2014, 406, 785-792.	1.9	25
100	3,4-Methylenedioxyamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration. Analytical and Bioanalytical Chemistry, 2014, 406, 587-599.	1.9	21
101	Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. Analytical and Bioanalytical Chemistry, 2014, 406, 1763-1780.	1.9	97
102	Validation of the only commercially available immunoassay for synthetic cathinones in urine: Randox Drugs of Abuse V Biochip Array Technology. Drug Testing and Analysis, 2014, 6, 728-738.	1.6	54
103	3,4-Methylenedioxypropylvalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography-high resolution mass spectrometry. Analytica Chimica Acta, 2014, 827, 54-63.	2.6	40
104	Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine. Forensic Science International, 2014, 241, 27-34.	1.3	46
105	Morphine and codeine concentrations in human urine following controlled poppy seeds administration of known opiate content. Forensic Science International, 2014, 241, 87-90.	1.3	36
106	Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography-tandem mass spectrometry. Journal of Chromatography A, 2014, 1327, 105-117.	1.8	92
107	Validation of a novel method to identify in utero ethanol exposure: simultaneous meconium extraction of fatty acid ethyl esters, ethyl glucuronide, and ethyl sulfate followed by LC-MS/MS quantification. Analytical and Bioanalytical Chemistry, 2014, 406, 1945-1955.	1.9	30
108	Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug and Alcohol Dependence, 2014, 144, 12-41.	1.6	572

#	ARTICLE	IF	CITATIONS
109	Urinary Cannabinoid Disposition in Occasional and Frequent Smokers: Is THC-Glucuronide in Sequential Urine Samples a Marker of Recent Use in Frequent Smokers?. <i>Clinical Chemistry</i> , 2014, 60, 361-372.	1.5	38
110	Rapid quantitative chiral amphetamines liquid chromatography-tandem mass spectrometry: Method in plasma and oral fluid with a cost-effective chiral derivatizing reagent. <i>Journal of Chromatography A</i> , 2014, 1358, 68-74.	1.8	35
111	Methamphetamine and Amphetamine Isomer Concentrations in Human Urine Following Controlled Vicks Vapoinhaler Administration. <i>Journal of Analytical Toxicology</i> , 2014, 38, 524-527.	1.7	19
112	Phase I and II Cannabinoid Disposition in Blood and Plasma of Occasional and Frequent Smokers Following Controlled Smoked Cannabis. <i>Clinical Chemistry</i> , 2014, 60, 631-643.	1.5	127
113	Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder. <i>Schizophrenia Research</i> , 2014, 152, 315-316.	1.1	5
114	Cannabinoids in oral fluid by on-site immunoassay and by GC-MS using two different oral fluid collection devices. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 4117-4128.	1.9	35
115	Maternal smoking during pregnancy and infant stress response: Test of a prenatal programming hypothesis. <i>Psychoneuroendocrinology</i> , 2014, 48, 29-40.	1.3	88
116	Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 7269-7279.	1.9	24
117	11-Nor-9-carboxy- Δ^9 -tetrahydrocannabinol quantification in human oral fluid by liquid chromatography-tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 6019-6027.	1.9	20
118	Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 4679-4689.	1.9	35
119	First Characterization of AKB-48 Metabolism, a Novel Synthetic Cannabinoid, Using Human Hepatocytes and High-Resolution Mass Spectrometry. <i>AAPS Journal</i> , 2013, 15, 1091-1098.	2.2	75
120	Simultaneous quantification of 28 synthetic cathinones and metabolites in urine by liquid chromatography-high resolution mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 9437-9448.	1.9	106
121	Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 8451-8461.	1.9	47
122	Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?. <i>Drug and Alcohol Dependence</i> , 2013, 130, 68-76.	1.6	29
123	Simultaneous quantification of Δ^9 -tetrahydrocannabinol, 11-nor-9-carboxy-tetrahydrocannabinol, cannabidiol and cannabinol in oral fluid by microflow-liquid chromatography-high resolution mass spectrometry. <i>Journal of Chromatography A</i> , 2013, 1297, 123-130.	1.8	38
124	Qualitative Confirmation of 9 Synthetic Cannabinoids and 20 Metabolites in Human Urine Using LC-MS/MS and Library Search. <i>Analytical Chemistry</i> , 2013, 85, 3730-3738.	3.2	108
125	Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 4067-4076.	1.9	21
126	Impact of Prolonged Cannabinoid Excretion in Chronic Daily Cannabis Smokers' Blood on Per Se Drugged Driving Laws. <i>Clinical Chemistry</i> , 2013, 59, 519-526.	1.5	127

#	ARTICLE	IF	CITATIONS
127	Around-the-clock oral THC effects on sleep in male chronic daily cannabis smokers. <i>American Journal on Addictions</i> , 2013, 22, 510-514.	1.3	33
128	In Vitro Stability of Free and Glucuronidated Cannabinoids in Blood and Plasma Following Controlled Smoked Cannabis. <i>Clinical Chemistry</i> , 2013, 59, 1108-1117.	1.5	45
129	CB1 Cannabinoid Receptor Antagonist Effects on Cortisol in Cannabis-Dependent Men. <i>American Journal of Drug and Alcohol Abuse</i> , 2012, 38, 114-119.	1.1	17
130	Simultaneous quantification of nicotine, cotinine, trans-3-hydroxycotinine, norcotinine and mecamylamine in human urine by liquid chromatography-tandem mass spectrometry. <i>Clinica Chimica Acta</i> , 2012, 413, 978-984.	0.5	26
131	Predictive model accuracy in estimating last 9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. <i>Drug and Alcohol Dependence</i> , 2012, 125, 313-319.	1.6	41
132	Psychomotor Performance, Subjective and Physiological Effects and Whole Blood 9-Tetrahydrocannabinol Concentrations in Heavy, Chronic Cannabis Smokers Following Acute Smoked Cannabis. <i>Journal of Analytical Toxicology</i> , 2012, 36, 405-412.	1.7	84
133	Cannabis in Sport. <i>Sports Medicine</i> , 2011, 41, 949-966.	3.1	64
134	Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. <i>Addiction</i> , 2011, 106, 499-506.	1.7	68
135	Simultaneous analysis of buprenorphine, methadone, cocaine, opiates and nicotine metabolites in sweat by liquid chromatography tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 400, 69-78.	1.9	46
136	Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled around-the-clock oral THC administration. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 599-607.	1.9	27
137	Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 1273-1283.	1.9	91
138	Oral Fluid Cannabinoids in Chronic, Daily Cannabis Smokers during Sustained, Monitored Abstinence. <i>Clinical Chemistry</i> , 2011, 57, 1127-1136.	1.5	69
139	Maternal Methadone Dose, Placental Methadone Concentrations, and Neonatal Outcomes. <i>Clinical Chemistry</i> , 2011, 57, 449-458.	1.5	48
140	Oral Fluid Testing: Promises and Pitfalls. <i>Clinical Chemistry</i> , 2011, 57, 805-810.	1.5	47
141	Identification of Recent Cannabis Use: Whole-Blood and Plasma Free and Glucuronidated Cannabinoid Pharmacokinetics following Controlled Smoked Cannabis Administration. <i>Clinical Chemistry</i> , 2011, 57, 1406-1414.	1.5	149
142	Validation of a two-dimensional gas chromatography mass spectrometry method for the simultaneous quantification of cannabidiol, 9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in plasma. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 397, 603-611.	1.9	38
143	Effect of hydrolysis on identifying prenatal cannabis exposure. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 397, 2335-2347.	1.9	26
144	High-throughput simultaneous analysis of buprenorphine, methadone, cocaine, opiates, nicotine, and metabolites in oral fluid by liquid chromatography tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 398, 915-924.	1.9	54

#	ARTICLE	IF	CITATIONS
145	Mice Lacking Multidrug Resistance Protein 1a Show Altered Dopaminergic Responses to Methylenedioxymethamphetamine (MDMA) in Striatum. <i>Neurotoxicity Research</i> , 2010, 18, 200-209.	1.3	6
146	Confirmatory analysis of buprenorphine, norbuprenorphine, and glucuronide metabolites in plasma by LCMSMS. Application to umbilical cord plasma from buprenorphine-maintained pregnant women. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 13-20.	1.2	23
147	Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome. <i>Addiction</i> , 2010, 105, 2151-2159.	1.7	34
148	Identifying Prenatal Cannabis Exposure and Effects of Concurrent Tobacco Exposure on Neonatal Growth. <i>Clinical Chemistry</i> , 2010, 56, 1442-1450.	1.5	106
149	Umbilical Cord Monitoring of In Utero Drug Exposure to Buprenorphine and Correlation with Maternal Dose and Neonatal Outcomes. <i>Journal of Analytical Toxicology</i> , 2010, 34, 498-505.	1.7	39
150	Disposition of Cannabinoids in Oral Fluid after Controlled Around-the-Clock Oral THC Administration. <i>Clinical Chemistry</i> , 2010, 56, 1261-1269.	1.5	43
151	Implications of Plasma Δ^9 -Tetrahydrocannabinol, 11-Hydroxy-THC, and 11-nor-9-Carboxy-THC Concentrations in Chronic Cannabis Smokers. <i>Journal of Analytical Toxicology</i> , 2009, 33, 469-477.	1.7	92
152	Simultaneous and sensitive measurement of nicotine, cotinine, trans-3 β -hydroxycotinine and norcotinine in human plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 3537-3542.	1.2	44
153	Simultaneous quantification of nicotine, opioids, cocaine, and metabolites in human fetal postmortem brain by liquid chromatography tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2009, 393, 1957-1965.	1.9	29
154	A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium. <i>Analytical and Bioanalytical Chemistry</i> , 2009, 393, 1977-1990.	1.9	58
155	Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in human placenta by liquid chromatography mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2009, 394, 513-522.	1.9	18
156	Optimization and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of nicotine, cotinine, trans-3 β -hydroxycotinine and norcotinine in human oral fluid. <i>Analytical and Bioanalytical Chemistry</i> , 2009, 395, 2349-2357.	1.9	33
157	Do Δ^9 -tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?. <i>Addiction</i> , 2009, 104, 2041-2048.	1.7	94
158	Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine-glucuronide and norbuprenorphine-glucuronide in human umbilical cord by liquid chromatography tandem mass spectrometry. <i>Forensic Science International</i> , 2009, 188, 144-151.	1.3	30
159	Development and validation of a liquid chromatography mass spectrometry assay for the simultaneous quantification of methadone, cocaine, opiates and metabolites in human umbilical cord. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 3065-3071.	1.2	28
160	Extended urinary Δ^9 -tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. <i>Drug and Alcohol Dependence</i> , 2009, 105, 24-32.	1.6	99
161	Oral Fluid Testing for Drugs of Abuse. <i>Clinical Chemistry</i> , 2009, 55, 1910-1931.	1.5	340
162	Intra- and Intersubject Whole Blood/Plasma Cannabinoid Ratios Determined by 2-Dimensional, Electron Impact GC-MS with Cryofocusing. <i>Clinical Chemistry</i> , 2009, 55, 1188-1195.	1.5	53

#	ARTICLE	IF	CITATIONS
163	Development and validation of a liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry method for simultaneous analysis of 10 amphetamine-, methamphetamine- and 3,4-methylenedioxyamphetamine-related (MDMA) analytes in human meconium. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 867, 104-104.	1.2	36
164	Development and validation of a solid-phase extraction gas chromatography-mass spectrometry method for the simultaneous quantification of methadone, heroin, cocaine and metabolites in sweat. <i>Analytical and Bioanalytical Chemistry</i> , 2008, 392, 115-127.	1.9	58
165	Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of buprenorphine, norbuprenorphine, and metabolites in human urine. <i>Analytical and Bioanalytical Chemistry</i> , 2008, 392, 903-911.	1.9	19
166	Quantification of nicotine, cotinine, trans-3-hydroxycotinine, nornicotine and norcotinine in human meconium by liquid chromatography/tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 863, 107-114.	1.2	55
167	A validated gas chromatographic-electron impact ionization mass spectrometric method for methamphetamine, methylenedioxyamphetamine (MDMA), and metabolites in mouse plasma and brain. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 876, 266-276.	1.2	18
168	Excretion of δ^9 -tetrahydrocannabinol in sweat. <i>Forensic Science International</i> , 2008, 174, 173-177.	1.3	52
169	Excretion of Methamphetamine and Amphetamine in Human Sweat Following Controlled Oral Methamphetamine Administration. <i>Clinical Chemistry</i> , 2008, 54, 172-180.	1.5	43
170	Urinary Elimination of 11-Nor-9-Carboxy- δ^9 -tetrahydrocannabinol in Cannabis Users During Continuously Monitored Abstinence. <i>Journal of Analytical Toxicology</i> , 2008, 32, 562-569.	1.7	92
171	Oral fluid as an alternative matrix to monitor opiate and cocaine use in substance-abuse treatment patients. <i>Drug and Alcohol Dependence</i> , 2007, 87, 258-267.	1.6	78
172	Cocaine and Metabolites Urinary Excretion after Controlled Smoked Administration*. <i>Journal of Analytical Toxicology</i> , 2007, 31, 462-468.	1.7	44
173	Human Cannabinoid Pharmacokinetics. <i>Chemistry and Biodiversity</i> , 2007, 4, 1770-1804.	1.0	833
174	Development and validation of a disk solid phase extraction and gas chromatography-mass spectrometry method for MDMA, MDA, HMMA, HMA, MDEA, methamphetamine and amphetamine in sweat. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 852, 450-458.	1.2	36
175	Methamphetamine Disposition in Oral Fluid, Plasma, and Urine. <i>Annals of the New York Academy of Sciences</i> , 2007, 1098, 104-121.	1.8	73
176	Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. <i>Psychopharmacology</i> , 2007, 194, 505-515.	1.5	144
177	Cannabinoid concentrations in hair from documented cannabis users. <i>Forensic Science International</i> , 2007, 169, 129-136.	1.3	95
178	Sensitive Gas Chromatography-Mass Spectrometry Method for Simultaneous Measurement of MDEA, MDMA, and Metabolites HMA, MDA, and HMMA in Human Urine. <i>Clinical Chemistry</i> , 2006, 52, 1728-1734.	1.5	28
179	Modern analytical technologies for the detection of drug abuse and doping. <i>Drug Discovery Today: Technologies</i> , 2006, 3, 49-57.	4.0	20
180	Estimating Time of Last Oral Ingestion of Cannabis From Plasma THC and THCCOOH Concentrations. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 540-544.	1.0	40

#	ARTICLE	IF	CITATIONS
181	A validated method for the determination of nicotine, cotinine, trans-3- β -hydroxycotinine, and norcotinine in human plasma using solid-phase extraction and liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2006, 41, 815-821.	0.7	39
182	A validated positive chemical ionization GC/MS method for the identification and quantification of amphetamine, opiates, cocaine, and metabolites in human postmortem brain. <i>Journal of Mass Spectrometry</i> , 2006, 41, 175-184.	0.7	28
183	Simultaneous determination of nicotine, cotinine, norcotinine, and trans-3- β -hydroxycotinine in human oral fluid using solid phase extraction and gas chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 814, 233-240.	1.2	60
184	Determination of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, 2-ethyl-5-methyl-3,3-diphenylpyrrolidine and methadone in meconium by liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 814, 369-373.	1.2	38
185	Liquid chromatographic/electrospray ionization tandem mass spectrometric analysis for the quantification of buprenorphine, norbuprenorphine, buprenorphine-3- β -D-glucuronide and norbuprenorphine-3- β -D-glucuronide in human plasma. <i>Journal of Mass Spectrometry</i> , 2005, 40, 70-74.	0.7	39
186	LC-ESI-MS/MS analysis for the quantification of morphine, codeine, morphine-3- β -D-glucuronide, morphine-6- β -D-glucuronide, and codeine-6- β -D-glucuronide in human urine. <i>Journal of Mass Spectrometry</i> , 2005, 40, 1412-1416.	0.7	55
187	Estimating the Time of Last Cannabis Use from Plasma δ^9 -Tetrahydrocannabinol and 11-nor-9-Carboxy- δ^9 -Tetrahydrocannabinol Concentrations. <i>Clinical Chemistry</i> , 2005, 51, 2289-2295.	1.5	76
188	Performance characteristics of the Cozart [®] RapiScan Oral Fluid Drug Testing System for opiates in comparison to ELISA and GC/MS following controlled codeine administration. <i>Forensic Science International</i> , 2004, 141, 41-48.	1.3	41
189	Validated method for the simultaneous determination of δ^9 -tetrahydrocannabinol (THC), 11-hydroxy-THC and 11-nor-9-carboxy-THC in human plasma using solid phase extraction and gas chromatography-mass spectrometry with positive chemical ionization. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 798, 145-154.	1.2	80
190	Urine drug testing for opioids, cocaine, and metabolites by direct injection liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2003, 17, 1665-1670.	0.7	113
191	Sensitivity and Specificity of the Cozart Microplate EIA Cocaine Oral Fluid at Proposed Screening and Confirmation Cutoffs. <i>Clinical Chemistry</i> , 2003, 49, 1498-1503.	1.5	20
192	Drug abuse's smallest victims: in utero drug exposure. <i>Forensic Science International</i> , 2002, 128, 20-30.	1.3	142
193	A Study of peptide-peptide interaction by matrix-assisted laser desorption/ionization. <i>Journal of the American Society for Mass Spectrometry</i> , 2001, 12, 88-96.	1.2	70
194	Blockade of Effects of Smoked Marijuana by the CB1-Selective Cannabinoid Receptor Antagonist SR141716. <i>Archives of General Psychiatry</i> , 2001, 58, 322.	13.8	437
195	Identification of Hydrocodone in Human Urine Following Controlled Codeine Administration. <i>Journal of Analytical Toxicology</i> , 2000, 24, 530-535.	1.7	70
196	Detection Times of Marijuana Metabolites in Urine by Immunoassay and GC-MS. <i>Journal of Analytical Toxicology</i> , 1995, 19, 443-449.	1.7	110